The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Friday’s jobs report could bolster the view that the American economy is holding steady, but an oil price shock could ...

NHS England has proposed a phased rollout of Eli Lilly’s obesity injection Mounjaro (tirzepatide), prioritizing patients with ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

The chip maker invested about $100 million in OpenAI's latest funding round, The Wall Street Journal reports. The CEO will need to convince investors that the company is still more than an auto maker.

The announcement could shake up the market for such injections, since the shortage designation allowed compounding pharmacies ...

The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...